Provention Bio Inc (NASDAQ:PRVB) insider Ashleigh Palmer bought 10,600 shares of Provention Bio stock in a transaction that occurred on Thursday, August 8th. The stock was purchased at an average price of $9.15 per share, for a total transaction of $96,990.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Ashleigh Palmer also recently made the following trade(s):
- On Tuesday, June 18th, Ashleigh Palmer bought 4,000 shares of Provention Bio stock. The stock was purchased at an average price of $10.83 per share, for a total transaction of $43,320.00.
NASDAQ:PRVB opened at $9.62 on Friday. The firm has a 50-day moving average of $11.35. Provention Bio Inc has a 12 month low of $1.52 and a 12 month high of $22.82.
Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in Provention Bio by 26.4% in the fourth quarter. BlackRock Inc. now owns 26,235 shares of the company’s stock valued at $46,000 after purchasing an additional 5,472 shares during the period. Acadian Asset Management LLC purchased a new position in Provention Bio in the second quarter valued at about $72,000. Wells Fargo & Company MN purchased a new position in Provention Bio in the second quarter valued at about $194,000. Bailard Inc. purchased a new position in Provention Bio in the second quarter valued at about $486,000. Finally, Sigma Planning Corp purchased a new position in Provention Bio in the second quarter valued at about $701,000. 1.88% of the stock is currently owned by institutional investors.
Several research analysts have commented on the company. Leerink Swann raised their price objective on Provention Bio from $17.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Zacks Investment Research lowered Provention Bio from a “buy” rating to a “hold” rating in a research report on Thursday, May 16th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective (up from $8.00) on shares of Provention Bio in a research report on Wednesday, June 26th. Finally, Chardan Capital assumed coverage on Provention Bio in a research report on Monday, June 10th. They issued a “buy” rating and a $20.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $16.75.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Further Reading: Diversification For Individual Investors
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.